Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia-Nanette Gann
Observed names:
C. Gann,
C.-N. Gann,
Claudia Gann,
Claudia N Gann
Institution:
BioNTech (Germany)
Observed institutions:
Boehringer Ingelheim (Germany),
Merck KGaA, Darmstadt (Germany),
University of Münster,
Janssen (Germany),
BioNTech (Germany),
Merck Healthcare KGaA, Darmstadt (Germany)
show all 6
OpenAlex ID:
A5089732826
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
2014
·
Martin Reck
, Rolf Kaiser
, et al.
·
The Lancet Oncology
·
1,031
PDF
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
2009
·
on behalf of the Deutsche Studiengruppe Multiples Myelom, DSMM
, Martin Kropff
, et al.
·
Annals of Hematology
·
48
PDF
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
2020
·
Hans Juergen Grote
, Zheng Feng
, et al.
·
Journal of Thoracic Oncology
·
42
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
2023
·
Kaiwen Wang
, Robyn Du
, et al.
·
JTO Clinical and Research Reports
·
13
PDF
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
2025
·
J.V. Heymach
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
9
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
2017
·
Birgit Gaschler-Markefski
, Patricia Sikken
, et al.
·
ESMO Open
·
9
PDF
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion
2024
·
Lily C Pham
, Lauryn Weller
, et al.
·
The Oncologist
·
8
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
2025
·
Solange Peters
, Stephen V. Liu
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC.
2026
·
Solange Peters
, Youngjoo Lee
, et al.
·
Journal of Clinical Oncology
·
6
PDF
Dose Definition for Intravenous Cyclophosphamide in Combination with Bortezomib/Dexamethasone for Remission Induction in Patients with Newly Diagnosed Multiple Myeloma.
2007
·
Martin Kropff
, Peter Liebisch
, et al.
·
Blood
·
6
Abstract PS1-13-25: Preliminary data from a global multicohort Phase2 randomized trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy for 1L/2L+ locally advanced/metastatic TNBC
2026
·
P. Schmid
, A. Williams
, et al.
·
Clinical Cancer Research
·
5
Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data
2026
·
Bhavana Pothuri
, Debra Richardson
, et al.
·
Gynecologic Oncology
·
4
Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations
2025
·
Erika P. Hamilton
, Jianqing Zhu
, et al.
·
Cancer Research
·
4
Innv-21. Complete Response to Adjuvant Tepotinib in a Patient With Newly Diagnosed Disseminated Glioblastoma (gbm) Harboring Met Amplification
2021
·
Lily Pham
, Claudia Gann
, et al.
·
Neuro-Oncology
·
4
Industry corner: perspectives and controversies - The challenges of patient access to new medicines
2016
·
C.-N. Gann
, N. Morsli
, et al.
·
Annals of Oncology
·
4
PDF
Bortezomib Retreatment in Relapsed Multiple Mycelia - A Retrospective Multicenter Survey.
2007
·
Irena Hrusovsky
, Berthold Emmerich
, et al.
·
Blood
·
4
PP01.120: Global Phase 2 Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
2026
·
J.V. Heymach
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
2
1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors
2024
·
I. Melero
, N.J. Lakhani
, et al.
·
Annals of Oncology
·
2
Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.
2016
·
Claudia-Nanette Gann
, Nassim Morsli
, et al.
·
Europe PMC (PubMed Central)
·
2
Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
2026
·
Jian Zhang
, Yehui Shi
, et al.
·
The Lancet Oncology
·
1
898 The PD-L1×VEGF-A bispecific antibody pumitamig shows enhanced binding to PD-L1 upon complexation with VEGF-A, promoting PD-L1 internalization and degradation in tumor cells
2026
·
Tonya Kueck
, Jan P Bogen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
25 Early ctDNA and QVT dynamics are associated with early clinical activity in patients with ES-SCLC treated with first-line pumitamig plus chemotherapy: an exploratory phase 2 analysis
2026
·
Secil Koseoglu
, Chiara Dalle Fratte
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
OA14.02: Pumitamig (PD-L1 x VEGF-A bsAb) + Elfetabart Drozuntecan (Elfe-D, B7H3 ADC) in Patients with Advanced/Metastatic Lung Cancer (NSCLC or SCLC
2026
·
A.J. Schoenfeld
, L. Sun
, et al.
·
Journal of Thoracic Oncology
PP01.58: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) in Combination with Chemotherapy in First-Line (1L) Non-Small Cell Lung Cancer (NSCLC) – ROSETTA Lung-02
2026
·
Solange Peters
, Stephen V. Liu
, et al.
·
Journal of Thoracic Oncology
149TiP ROSETTA Lung-02: A global phase II/III, randomized, open-label trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, in combination with chemotherapy in patients (pts) with first-line non-small cell lung cancer
2026
·
S. Peters
, Y. Lee
, et al.
·
ESMO Open
Show more works
View as search
Works count:
25
Citation count:
1,211
H-index:
7
I10-index:
4
Year
Topic
Type